Immutep Completes Patient Enrollment for Phase II AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company in the clinical trial phase, has announced the completion of patient enrolment for the Phase II portion of their AIPAC-003 (Active Immunotherapy and PAClitaxel) clinical trial. This trial involves testing treatments for patients with metastatic hormone receptor-positive (HR+), HER2-negative/low, or triple-negative breast cancer who have previously exhausted endocrine therapy, including cyclin-dependent kinase 4/6 (CDK4/6) inhibitors.

In this Phase II trial, a total of 65 patients have been enrolled. These patients are located across 22 clinical sites in Europe and the United States. Participants were randomly assigned, with a ratio of 1:1, to receive either a 30mg or 90mg dose of eftilagimod alpha (“efti”) in combination with paclitaxel. The primary objective is to determine the optimal biological dose that aligns with the FDA’s Project Optimus initiative.

The company has stated that further information will be provided after the stages of data collection, data cleaning, and data analysis are completed. For more details about the trial, reference can be made to clinicaltrials.gov under the identifier NCT05747794.

Immutep stands out in the biotechnology sector due to its focus on developing LAG-3 immunotherapy for cancer and autoimmune diseases. The company is at the forefront of research and development related to Lymphocyte Activation Gene-3 (LAG-3), a molecule that plays a role in regulating immune responses. Their product portfolio is designed to either stimulate or suppress the immune system, depending on the therapeutic needs.

The company’s commitment is to utilize their expertise in LAG-3 to develop innovative treatment options for patients and create value for shareholders. Their dedication is reflected in their ongoing clinical trials and research efforts aimed at bringing transformative therapies to the market. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!